Over 11 million people are diagnosed with cancer every year worldwide. Breast cancer is the most prevalent and lung cancer is the most common cause of cancer death.
We are a world leader in the treatment of this devastating disease, with a broad range of products including Casodex , Arimidex and Zoladex. The latest additions to our range are Faslodex for breast cancer and Iressa for lung cancer. We are committed to delivering continued innovation in the fight against cancer. Some of our anti-cancer drugs are also used to treat non-malignant illnesses, such as gynaecological conditions.
Product range
More information about our products is available by clicking on the names below.
| Brand Name | Generic Name |
|---|---|
| Arimidex | anastrozole |
| Casodex, Cosudex | bicalutamide |
| Faslodex | fulvestrant |
| Iressa | gefitinib, ZD1839 |
| Nolvadex, Istubal, Valodex | tamoxifen citrate |
| Tomudex (now a trademark of Hospira) | raltitrexed |
| Zoladex | goserelin acetate |
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 20-Nov-2009 22:49 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
